- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 20.11. | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx | ||
| 13.11. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.09. | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.09. | EXTRAWELL PHAR (00858): COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND BUSINESS UPDATE | - | HKEx | ||
| 22.08. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 AUGUST 2025 | 2 | HKEx | ||
| 15.08. | EXTRAWELL PHAR (00858): ISSUE OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 22 AUGUST 2025 AT 11:00 A.M. | - | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): ANNUAL REPORT 2025 | 3 | HKEx | ||
| 03.07. | EXTRAWELL PHAR (00858): TERMS OF REFERENCE OF NOMINATION COMMITTEE | 1 | HKEx | ||
| 30.06. | EXTRAWELL PHAR (00858): ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2025 | 1 | HKEx | ||
| 23.06. | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 17.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | - | HKEx |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 71,34 | +0,20 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment... ► Artikel lesen | |
| CSPC PHARMA | 0,894 | +1,45 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN ... | ||
| SELLAS LIFE SCIENCES | 1,376 | -1,15 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 21,350 | -1,02 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,630 | +2,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 508,40 | -1,17 % | Madrigal Pharmaceuticals: Aktie erreicht Rekordhoch von 578,8 US-Dollar | ||
| ENZON PHARMACEUTICALS | 0,030 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,778 | -2,52 % | Piper Sandler startet Coverage für Opus Genetics mit "Overweight" und 250 % Kurspotenzial | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 5,550 | +2,78 % | Savara Inc.: Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 | - The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% - - Changes in DLco%, the Primary Endpoint in IMPALA-2, Were... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 4,840 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update | NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 4,550 | +4,60 % | Biodexa Pharmaceuticals PLC: Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP | November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,070 | +3,88 % | NovaBay Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| NEURIZON THERAPEUTICS | 0,053 | +8,16 % | Neurizon Therapeutics Limited: Elanco executive appointed as Neurizon's Board Observer | MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.